
StockWatch: Investors Hungry for Lilly after Diabetes Pill Aces Phase III Trial
No sooner did Eli Lilly (NYSE: LLY)’s oral diabetes candidate orforglipron make history Thursday as the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to ace a Phase III trial when investors roared their approval with a buying …